https://charts.traderzeitung.de/phases/US14817C1071
string(1443) "{"isin":"US14817C1071","name":"Filana Therapeutics Inc","stock_id_xnas":8840378,"stock_id_xnys":null,"generated_at":"2026-08-21 04:54:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":0.901,"close_at":"2026-08-18 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.872,"close_at":"2026-08-18 21:57:00","complete":true,"perf_pct":-3.2186},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.983,"close_at":"2026-08-19 21:54:00","complete":true,"perf_pct":12.7294},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":0.962,"close_at":"2026-08-19 22:00:00","complete":true,"perf_pct":-2.1363}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.936,"close_at":"2026-08-20 21:41:00","complete":true,"perf_pct":-2.7027},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Filana Therapeutics Aktie News & Nachrichten

Filana Therapeutics Aktie News & Nachrichten

[WKN: A2PGL8 | Symbol: FLNA]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Cassava Sciences: Insiderkäufe durch den CEO summieren sich auf 534.743 USD

In den vergangenen Monaten hat Cassava Sciences (SAVA) eine strategische Neuausrichtung vorgenommen,...

Stocks in Action USA: Robinhood (HOOD), DocuSign (DOCU), Cassava Sciences (SAVA)

Robinhood Markets (HOOD) – die relative Kursstärke bringt die Aktie fast auf ein neues Jahreshoch!...

Cassava Sciences Inc.: Einigung mit der SEC weckt Kaufinteresse - H.C. Wainwright sieht 330 % Kurspotenzial

Cassava Sciences Inc. (SAVA) ist ein Biotech, welcher sich auf Behandlungsmethoden für neurodegenerative...

  • 1